Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Active Ankylosing Spondylitis

Investigator: Lianne S. Gensler, MD
Sponsor: Celgene Corporation

Location(s): United States


Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.